Members of a federal commission charged with studying COVID-19 in nursing homes have been named.
Jay Schnitzer
As of yesterday, CDC’s official tally of COVID-19 deaths was 119,055. The estimates vary quite a bit, but there’s no question that a sizable proportion of those deaths have occurred among residents of nursing homes and other long-term facilities. As of June 18, the Kaiser Family Foundation’s count was 50,185 in 41 states. In early June, preliminary data from CMS showed 29,457 deaths in nursing home from COVID-19.
CMS and the CDC have issued COVID-19 guidelines for nursing homes. But the way that COVID-19 has played out in the nation's nursing homes is a complex situation, often with human suffering attached. A story in today's New York Times reports that some nursing homes have cleared out residents who don't have COVID-19 because the reimbursment rate for COVID-19 is higher. "With nursing homes not allowing visitors, there is less outside scrutiny of their practices," reports the newspaper. "Fifteen state-funded ombudsmaen said in intereviews tht some homes appear to be taking advantage of that void to evict vulnerable residents."
In late April, CMS announced that it would be setting up an independent Coronavirus Commission for Safety and Quality in Nursing Homes to examine COVID-19-related issues in depth, including identification of best practices for rapid identification and mitigation of transmission and for care delivery. The MITRE Corporation, a federal contractor and research organization with offices in Bedford, Massachusetts, and McLean, Virginia, was hired to set up and run the commission.
Related: In Harm's Way: Nursing Homes in the COVID-19 Pandemic
Last week, CMS and MITRE announced that it had picked the 25 members of the commission out of a pool of 800 applicants. Jay Schnitzer, Ph.D., M.D., MITRE’s chief technology and medical officer, will serve as the commissioner’s moderator.
Here is a list of the 25 members of the commission:
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More